Multizonal observational study conducted by clinical practitioners on evolocumab use in subjects with hyperlipidemia in Saudi Arabia and Kuwait: Results from the ZERBINI study
Dyslipidemia is a prevalent condition with significant morbidity and mortality across the world, including in the Arabian Gulf. The present study aimed to describe the characteristics of patients receiving evolocumab in clinical practice. ZERBINI was a multi-country, observational, retrospective/pro...
Saved in:
| Published in | PloS one Vol. 18; no. 1; p. e0278821 |
|---|---|
| Main Authors | , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
United States
Public Library of Science
20.01.2023
Public Library of Science (PLoS) |
| Subjects | |
| Online Access | Get full text |
| ISSN | 1932-6203 1932-6203 |
| DOI | 10.1371/journal.pone.0278821 |
Cover
Loading…
| Abstract | Dyslipidemia is a prevalent condition with significant morbidity and mortality across the world, including in the Arabian Gulf. The present study aimed to describe the characteristics of patients receiving evolocumab in clinical practice.
ZERBINI was a multi-country, observational, retrospective/prospective study of subjects receiving evolocumab as part of routine clinical management of their hyperlipidemia. This regional publication reports on adult participants from Saudi Arabia and Kuwait who have had ≥1 dose of evolocumab before enrollment and ≤6 months' prior exposure to evolocumab. Patient characteristics and treatment persistence data were collected in addition to baseline and follow-up data up to 12 months post-evolocumab initiation.
Overall, 225 patients were included from two sites, Saudi Arabia (N = 155) and Kuwait (N = 70). Mean age was comparable across sites and most patients had baseline coronary artery disease and/or hypertension. Baseline LDL-C levels (mean ± SD 3.6 ± 1.4 mmol/L in Saudi Arabia, 3.1 ± 1.4 mmol/L in Kuwait) were reduced by approximately 57%-62% in the first 6 months after evolocumab initiation (1.5 ± 1.2 mmol/L in Saudi Arabia [n = 63], 1.2 ± 0.8 mmol/L in Kuwait [n = 28]). This decrease was maintained over the 12-month follow-up period. Most patients achieved ACC 2018 LDL-C goals (<1.8 mmol/L; 74.6% in Saudi Arabia, 93.1% in Kuwait) and ESC 2019 LDL-C goals (<1.4 mmol/L; 66.7% in Saudi Arabia, 75.9% in Kuwait) in the first 6 months after evolocumab initiation. Medication persistence with evolocumab was high (up to 90.7%). Evolocumab had a favorable safety profile and no treatment-emergent adverse events were observed at either site.
Evolocumab is an effective lipid-lowering treatment in local populations. LDL-C goal achievement is increased when evolocumab is added to background lipid-lowering therapy with high tolerability and persistence. Long-term follow-up and large-scale data are needed to further support these observations. |
|---|---|
| AbstractList | Objectives
Dyslipidemia is a prevalent condition with significant morbidity and mortality across the world, including in the Arabian Gulf. The present study aimed to describe the characteristics of patients receiving evolocumab in clinical practice.
Methods
ZERBINI was a multi-country, observational, retrospective/prospective study of subjects receiving evolocumab as part of routine clinical management of their hyperlipidemia. This regional publication reports on adult participants from Saudi Arabia and Kuwait who have had ≥1 dose of evolocumab before enrollment and ≤6 months’ prior exposure to evolocumab. Patient characteristics and treatment persistence data were collected in addition to baseline and follow-up data up to 12 months post-evolocumab initiation.
Results
Overall, 225 patients were included from two sites, Saudi Arabia (N = 155) and Kuwait (N = 70). Mean age was comparable across sites and most patients had baseline coronary artery disease and/or hypertension. Baseline LDL-C levels (mean ± SD 3.6 ± 1.4 mmol/L in Saudi Arabia, 3.1 ± 1.4 mmol/L in Kuwait) were reduced by approximately 57%–62% in the first 6 months after evolocumab initiation (1.5 ± 1.2 mmol/L in Saudi Arabia [n = 63], 1.2 ± 0.8 mmol/L in Kuwait [n = 28]). This decrease was maintained over the 12-month follow-up period. Most patients achieved ACC 2018 LDL-C goals (<1.8 mmol/L; 74.6% in Saudi Arabia, 93.1% in Kuwait) and ESC 2019 LDL-C goals (<1.4 mmol/L; 66.7% in Saudi Arabia, 75.9% in Kuwait) in the first 6 months after evolocumab initiation. Medication persistence with evolocumab was high (up to 90.7%). Evolocumab had a favorable safety profile and no treatment-emergent adverse events were observed at either site.
Conclusion
Evolocumab is an effective lipid-lowering treatment in local populations. LDL-C goal achievement is increased when evolocumab is added to background lipid-lowering therapy with high tolerability and persistence. Long-term follow-up and large-scale data are needed to further support these observations. Dyslipidemia is a prevalent condition with significant morbidity and mortality across the world, including in the Arabian Gulf. The present study aimed to describe the characteristics of patients receiving evolocumab in clinical practice.OBJECTIVESDyslipidemia is a prevalent condition with significant morbidity and mortality across the world, including in the Arabian Gulf. The present study aimed to describe the characteristics of patients receiving evolocumab in clinical practice.ZERBINI was a multi-country, observational, retrospective/prospective study of subjects receiving evolocumab as part of routine clinical management of their hyperlipidemia. This regional publication reports on adult participants from Saudi Arabia and Kuwait who have had ≥1 dose of evolocumab before enrollment and ≤6 months' prior exposure to evolocumab. Patient characteristics and treatment persistence data were collected in addition to baseline and follow-up data up to 12 months post-evolocumab initiation.METHODSZERBINI was a multi-country, observational, retrospective/prospective study of subjects receiving evolocumab as part of routine clinical management of their hyperlipidemia. This regional publication reports on adult participants from Saudi Arabia and Kuwait who have had ≥1 dose of evolocumab before enrollment and ≤6 months' prior exposure to evolocumab. Patient characteristics and treatment persistence data were collected in addition to baseline and follow-up data up to 12 months post-evolocumab initiation.Overall, 225 patients were included from two sites, Saudi Arabia (N = 155) and Kuwait (N = 70). Mean age was comparable across sites and most patients had baseline coronary artery disease and/or hypertension. Baseline LDL-C levels (mean ± SD 3.6 ± 1.4 mmol/L in Saudi Arabia, 3.1 ± 1.4 mmol/L in Kuwait) were reduced by approximately 57%-62% in the first 6 months after evolocumab initiation (1.5 ± 1.2 mmol/L in Saudi Arabia [n = 63], 1.2 ± 0.8 mmol/L in Kuwait [n = 28]). This decrease was maintained over the 12-month follow-up period. Most patients achieved ACC 2018 LDL-C goals (<1.8 mmol/L; 74.6% in Saudi Arabia, 93.1% in Kuwait) and ESC 2019 LDL-C goals (<1.4 mmol/L; 66.7% in Saudi Arabia, 75.9% in Kuwait) in the first 6 months after evolocumab initiation. Medication persistence with evolocumab was high (up to 90.7%). Evolocumab had a favorable safety profile and no treatment-emergent adverse events were observed at either site.RESULTSOverall, 225 patients were included from two sites, Saudi Arabia (N = 155) and Kuwait (N = 70). Mean age was comparable across sites and most patients had baseline coronary artery disease and/or hypertension. Baseline LDL-C levels (mean ± SD 3.6 ± 1.4 mmol/L in Saudi Arabia, 3.1 ± 1.4 mmol/L in Kuwait) were reduced by approximately 57%-62% in the first 6 months after evolocumab initiation (1.5 ± 1.2 mmol/L in Saudi Arabia [n = 63], 1.2 ± 0.8 mmol/L in Kuwait [n = 28]). This decrease was maintained over the 12-month follow-up period. Most patients achieved ACC 2018 LDL-C goals (<1.8 mmol/L; 74.6% in Saudi Arabia, 93.1% in Kuwait) and ESC 2019 LDL-C goals (<1.4 mmol/L; 66.7% in Saudi Arabia, 75.9% in Kuwait) in the first 6 months after evolocumab initiation. Medication persistence with evolocumab was high (up to 90.7%). Evolocumab had a favorable safety profile and no treatment-emergent adverse events were observed at either site.Evolocumab is an effective lipid-lowering treatment in local populations. LDL-C goal achievement is increased when evolocumab is added to background lipid-lowering therapy with high tolerability and persistence. Long-term follow-up and large-scale data are needed to further support these observations.CONCLUSIONEvolocumab is an effective lipid-lowering treatment in local populations. LDL-C goal achievement is increased when evolocumab is added to background lipid-lowering therapy with high tolerability and persistence. Long-term follow-up and large-scale data are needed to further support these observations. Objectives Dyslipidemia is a prevalent condition with significant morbidity and mortality across the world, including in the Arabian Gulf. The present study aimed to describe the characteristics of patients receiving evolocumab in clinical practice. Methods ZERBINI was a multi-country, observational, retrospective/prospective study of subjects receiving evolocumab as part of routine clinical management of their hyperlipidemia. This regional publication reports on adult participants from Saudi Arabia and Kuwait who have had [greater than or equal to]1 dose of evolocumab before enrollment and [less than or equal to]6 months' prior exposure to evolocumab. Patient characteristics and treatment persistence data were collected in addition to baseline and follow-up data up to 12 months post-evolocumab initiation. Results Overall, 225 patients were included from two sites, Saudi Arabia (N = 155) and Kuwait (N = 70). Mean age was comparable across sites and most patients had baseline coronary artery disease and/or hypertension. Baseline LDL-C levels (mean ± SD 3.6 ± 1.4 mmol/L in Saudi Arabia, 3.1 ± 1.4 mmol/L in Kuwait) were reduced by approximately 57%-62% in the first 6 months after evolocumab initiation (1.5 ± 1.2 mmol/L in Saudi Arabia [n = 63], 1.2 ± 0.8 mmol/L in Kuwait [n = 28]). This decrease was maintained over the 12-month follow-up period. Most patients achieved ACC 2018 LDL-C goals (<1.8 mmol/L; 74.6% in Saudi Arabia, 93.1% in Kuwait) and ESC 2019 LDL-C goals (<1.4 mmol/L; 66.7% in Saudi Arabia, 75.9% in Kuwait) in the first 6 months after evolocumab initiation. Medication persistence with evolocumab was high (up to 90.7%). Evolocumab had a favorable safety profile and no treatment-emergent adverse events were observed at either site. Conclusion Evolocumab is an effective lipid-lowering treatment in local populations. LDL-C goal achievement is increased when evolocumab is added to background lipid-lowering therapy with high tolerability and persistence. Long-term follow-up and large-scale data are needed to further support these observations. Dyslipidemia is a prevalent condition with significant morbidity and mortality across the world, including in the Arabian Gulf. The present study aimed to describe the characteristics of patients receiving evolocumab in clinical practice. ZERBINI was a multi-country, observational, retrospective/prospective study of subjects receiving evolocumab as part of routine clinical management of their hyperlipidemia. This regional publication reports on adult participants from Saudi Arabia and Kuwait who have had [greater than or equal to]1 dose of evolocumab before enrollment and [less than or equal to]6 months' prior exposure to evolocumab. Patient characteristics and treatment persistence data were collected in addition to baseline and follow-up data up to 12 months post-evolocumab initiation. Overall, 225 patients were included from two sites, Saudi Arabia (N = 155) and Kuwait (N = 70). Mean age was comparable across sites and most patients had baseline coronary artery disease and/or hypertension. Baseline LDL-C levels (mean ± SD 3.6 ± 1.4 mmol/L in Saudi Arabia, 3.1 ± 1.4 mmol/L in Kuwait) were reduced by approximately 57%-62% in the first 6 months after evolocumab initiation (1.5 ± 1.2 mmol/L in Saudi Arabia [n = 63], 1.2 ± 0.8 mmol/L in Kuwait [n = 28]). This decrease was maintained over the 12-month follow-up period. Most patients achieved ACC 2018 LDL-C goals (<1.8 mmol/L; 74.6% in Saudi Arabia, 93.1% in Kuwait) and ESC 2019 LDL-C goals (<1.4 mmol/L; 66.7% in Saudi Arabia, 75.9% in Kuwait) in the first 6 months after evolocumab initiation. Medication persistence with evolocumab was high (up to 90.7%). Evolocumab had a favorable safety profile and no treatment-emergent adverse events were observed at either site. Evolocumab is an effective lipid-lowering treatment in local populations. LDL-C goal achievement is increased when evolocumab is added to background lipid-lowering therapy with high tolerability and persistence. Long-term follow-up and large-scale data are needed to further support these observations. Dyslipidemia is a prevalent condition with significant morbidity and mortality across the world, including in the Arabian Gulf. The present study aimed to describe the characteristics of patients receiving evolocumab in clinical practice. ZERBINI was a multi-country, observational, retrospective/prospective study of subjects receiving evolocumab as part of routine clinical management of their hyperlipidemia. This regional publication reports on adult participants from Saudi Arabia and Kuwait who have had ≥1 dose of evolocumab before enrollment and ≤6 months' prior exposure to evolocumab. Patient characteristics and treatment persistence data were collected in addition to baseline and follow-up data up to 12 months post-evolocumab initiation. Overall, 225 patients were included from two sites, Saudi Arabia (N = 155) and Kuwait (N = 70). Mean age was comparable across sites and most patients had baseline coronary artery disease and/or hypertension. Baseline LDL-C levels (mean ± SD 3.6 ± 1.4 mmol/L in Saudi Arabia, 3.1 ± 1.4 mmol/L in Kuwait) were reduced by approximately 57%-62% in the first 6 months after evolocumab initiation (1.5 ± 1.2 mmol/L in Saudi Arabia [n = 63], 1.2 ± 0.8 mmol/L in Kuwait [n = 28]). This decrease was maintained over the 12-month follow-up period. Most patients achieved ACC 2018 LDL-C goals (<1.8 mmol/L; 74.6% in Saudi Arabia, 93.1% in Kuwait) and ESC 2019 LDL-C goals (<1.4 mmol/L; 66.7% in Saudi Arabia, 75.9% in Kuwait) in the first 6 months after evolocumab initiation. Medication persistence with evolocumab was high (up to 90.7%). Evolocumab had a favorable safety profile and no treatment-emergent adverse events were observed at either site. Evolocumab is an effective lipid-lowering treatment in local populations. LDL-C goal achievement is increased when evolocumab is added to background lipid-lowering therapy with high tolerability and persistence. Long-term follow-up and large-scale data are needed to further support these observations. Objectives Dyslipidemia is a prevalent condition with significant morbidity and mortality across the world, including in the Arabian Gulf. The present study aimed to describe the characteristics of patients receiving evolocumab in clinical practice. Methods ZERBINI was a multi-country, observational, retrospective/prospective study of subjects receiving evolocumab as part of routine clinical management of their hyperlipidemia. This regional publication reports on adult participants from Saudi Arabia and Kuwait who have had ≥1 dose of evolocumab before enrollment and ≤6 months’ prior exposure to evolocumab. Patient characteristics and treatment persistence data were collected in addition to baseline and follow-up data up to 12 months post-evolocumab initiation. Results Overall, 225 patients were included from two sites, Saudi Arabia (N = 155) and Kuwait (N = 70). Mean age was comparable across sites and most patients had baseline coronary artery disease and/or hypertension. Baseline LDL-C levels (mean ± SD 3.6 ± 1.4 mmol/L in Saudi Arabia, 3.1 ± 1.4 mmol/L in Kuwait) were reduced by approximately 57%–62% in the first 6 months after evolocumab initiation (1.5 ± 1.2 mmol/L in Saudi Arabia [n = 63], 1.2 ± 0.8 mmol/L in Kuwait [n = 28]). This decrease was maintained over the 12-month follow-up period. Most patients achieved ACC 2018 LDL-C goals (<1.8 mmol/L; 74.6% in Saudi Arabia, 93.1% in Kuwait) and ESC 2019 LDL-C goals (<1.4 mmol/L; 66.7% in Saudi Arabia, 75.9% in Kuwait) in the first 6 months after evolocumab initiation. Medication persistence with evolocumab was high (up to 90.7%). Evolocumab had a favorable safety profile and no treatment-emergent adverse events were observed at either site. Conclusion Evolocumab is an effective lipid-lowering treatment in local populations. LDL-C goal achievement is increased when evolocumab is added to background lipid-lowering therapy with high tolerability and persistence. Long-term follow-up and large-scale data are needed to further support these observations. ObjectivesDyslipidemia is a prevalent condition with significant morbidity and mortality across the world, including in the Arabian Gulf. The present study aimed to describe the characteristics of patients receiving evolocumab in clinical practice.MethodsZERBINI was a multi-country, observational, retrospective/prospective study of subjects receiving evolocumab as part of routine clinical management of their hyperlipidemia. This regional publication reports on adult participants from Saudi Arabia and Kuwait who have had ≥1 dose of evolocumab before enrollment and ≤6 months' prior exposure to evolocumab. Patient characteristics and treatment persistence data were collected in addition to baseline and follow-up data up to 12 months post-evolocumab initiation.ResultsOverall, 225 patients were included from two sites, Saudi Arabia (N = 155) and Kuwait (N = 70). Mean age was comparable across sites and most patients had baseline coronary artery disease and/or hypertension. Baseline LDL-C levels (mean ± SD 3.6 ± 1.4 mmol/L in Saudi Arabia, 3.1 ± 1.4 mmol/L in Kuwait) were reduced by approximately 57%-62% in the first 6 months after evolocumab initiation (1.5 ± 1.2 mmol/L in Saudi Arabia [n = 63], 1.2 ± 0.8 mmol/L in Kuwait [n = 28]). This decrease was maintained over the 12-month follow-up period. Most patients achieved ACC 2018 LDL-C goals (<1.8 mmol/L; 74.6% in Saudi Arabia, 93.1% in Kuwait) and ESC 2019 LDL-C goals (<1.4 mmol/L; 66.7% in Saudi Arabia, 75.9% in Kuwait) in the first 6 months after evolocumab initiation. Medication persistence with evolocumab was high (up to 90.7%). Evolocumab had a favorable safety profile and no treatment-emergent adverse events were observed at either site.ConclusionEvolocumab is an effective lipid-lowering treatment in local populations. LDL-C goal achievement is increased when evolocumab is added to background lipid-lowering therapy with high tolerability and persistence. Long-term follow-up and large-scale data are needed to further support these observations. |
| Audience | Academic |
| Author | Al Faraidy, Khalid Shehri, Mohamed Akbar, Mousa Abdin Hussein, Gamal Al Qudaimi, Ahmad Awan, Zuhier Emara, Alaa Aljarallah, Mohammad Dashti, Raja Al Nouri, Fahad Essam, Ahmed |
| AuthorAffiliation | 3 Cardiac Center Armed Forces Hospital Southern Region, Khamis Mushait, Saudi Arabia 5 Adult Cardiology Department, Cardiac Center North West Armed Forces King Salman Hospital, Tabuk, Saudi Arabia 7 Saud Al-babtain Cardiac Center, Dammam, Saudi Arabia 11 Medical Department, Amgen Saudi, Saudi Arabia 8 Cardiovascular Prevention Unit, Prince Sultan Cardiac Centre, Riyadh, Saudi Arabia 1 KFMMC Cardiac Center, Interventional Cardiologist, King Fahd Military Medical Complex, Dharan, Saudi Arabia 2 Cardiology Unit, Sabah Hospital, Kuwait City, Kuwait 6 Sabah Al-Ahmad Cardiac Center, Amiri Hospital, Kuwait City, Kuwait 10 Medical Affair Department, Amgen Middle East, Dubai, United Arab of Emirates Internal Medicine 1, ITALY 4 Sabah Al Ahmed Cardiac Center, Al-Amiri Hospital, Kuwait City, Kuwait 9 King Abdulaziz University, Clinical Biochemistry Jeddah University, Jeddah, Saudi Arabia |
| AuthorAffiliation_xml | – name: 11 Medical Department, Amgen Saudi, Saudi Arabia – name: 1 KFMMC Cardiac Center, Interventional Cardiologist, King Fahd Military Medical Complex, Dharan, Saudi Arabia – name: 4 Sabah Al Ahmed Cardiac Center, Al-Amiri Hospital, Kuwait City, Kuwait – name: 6 Sabah Al-Ahmad Cardiac Center, Amiri Hospital, Kuwait City, Kuwait – name: 8 Cardiovascular Prevention Unit, Prince Sultan Cardiac Centre, Riyadh, Saudi Arabia – name: 3 Cardiac Center Armed Forces Hospital Southern Region, Khamis Mushait, Saudi Arabia – name: 5 Adult Cardiology Department, Cardiac Center North West Armed Forces King Salman Hospital, Tabuk, Saudi Arabia – name: Internal Medicine 1, ITALY – name: 2 Cardiology Unit, Sabah Hospital, Kuwait City, Kuwait – name: 7 Saud Al-babtain Cardiac Center, Dammam, Saudi Arabia – name: 9 King Abdulaziz University, Clinical Biochemistry Jeddah University, Jeddah, Saudi Arabia – name: 10 Medical Affair Department, Amgen Middle East, Dubai, United Arab of Emirates |
| Author_xml | – sequence: 1 givenname: Khalid orcidid: 0000-0003-0237-9782 surname: Al Faraidy fullname: Al Faraidy, Khalid – sequence: 2 givenname: Mousa surname: Akbar fullname: Akbar, Mousa – sequence: 3 givenname: Mohamed surname: Shehri fullname: Shehri, Mohamed – sequence: 4 givenname: Mohammad surname: Aljarallah fullname: Aljarallah, Mohammad – sequence: 5 givenname: Gamal surname: Abdin Hussein fullname: Abdin Hussein, Gamal – sequence: 6 givenname: Raja surname: Dashti fullname: Dashti, Raja – sequence: 7 givenname: Ahmad surname: Al Qudaimi fullname: Al Qudaimi, Ahmad – sequence: 8 givenname: Fahad surname: Al Nouri fullname: Al Nouri, Fahad – sequence: 9 givenname: Zuhier surname: Awan fullname: Awan, Zuhier – sequence: 10 givenname: Ahmed surname: Essam fullname: Essam, Ahmed – sequence: 11 givenname: Alaa surname: Emara fullname: Emara, Alaa |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/36662739$$D View this record in MEDLINE/PubMed |
| BookMark | eNqNk9tuEzEQhleoiB7gDRBYQkJwkeBd77EXSKUqEFGo1AIX3Fg-jBtHzjr40FJeilfEm6RVU1UI7cXujL_5Pf7Xs5tt9baHLHua43FOmvzNzEbXMzNepPQYF03bFvmDbCfvSDGqC0y2bn1vZ7vezzCuSFvXj7JtUtd10ZBuJ_vzOZqgf9ukhCz34C5Y0MvIhyivkLC9jCKARDwFRvdapLWFYyLoAQTnke0RXFhjRZwzjqIHpHvkI5-BCB5d6jBF06sFOKMXWsJcs2H9jEWp0YFjPMWsl-hTvGQ67KNT8Kklj5SzcxSmgH4cnb6bfJmsGnqcPVTMeHiyfu9l394ffT38ODo--TA5PDgeiborwqhtGZS5YoKwnCkpK9FUnayTRTlngjcKFJcCl6rF0OJC8E5Cp2QnVF6VTVmSvez5SndhrKdrrz0tmropi6oiAzFZEdKyGV04PWfuilqm6TJh3TllLmhhgGJSdjgnogJelVgqrjqOCW9VVZQVwTJpvV3vFvkcpIA-OGY2RDdXej2l5_aCdm3V4i5PAq_WAs7-jOADnWsvwBjWg43LvtuCYFIM6Is76P2nW1PnLB1A98qmfcUgSg8aQrqyqLsmUeN7qPQMvzldHVA65TcKXm8UJCbAr3DOovd0cnb6_-zJ90325S12CsyEqbcmDlfUb4LPbjt9Y_H1RCSgXAHCWe8dqBskx3QYvGu76DB4dD14qWz_TpnQYTlKyRFt_l38F4fjOIU |
| CitedBy_id | crossref_primary_10_1186_s13098_025_01587_x crossref_primary_10_1016_j_jsps_2024_102203 crossref_primary_10_31083_j_rcm2505190 crossref_primary_10_1007_s40119_023_00334_5 crossref_primary_10_18502_dmj_v7i4_17801 |
| Cites_doi | 10.1016/j.jacc.2020.11.010 10.1097/MD.0000000000014400 10.1093/eurheartj/ehz455 10.1016/j.ophtha.2021.10.009 10.1371/journal.pone.0084350 10.1007/s12325-020-01259-4 10.1155/2015/235101 10.1016/j.atherosclerosis.2018.12.026 10.1186/s41983-021-00354-9 10.1161/JAHA.118.009778 10.1161/CIRCOUTCOMES.120.006646 10.1016/S0140-6736(20)32233-9 10.1111/1756-185X.13960 10.1371/journal.pone.0251560 10.1056/NEJMoa1615664 10.1016/j.amjmed.2011.12.013 10.1161/JAHA.117.006910 10.1016/j.jacc.2019.08.1024 10.1016/j.atherosclerosis.2017.05.018 10.1038/nrcardio.2017.138 10.5551/jat.31179 10.1186/s12916-020-01792-7 10.1161/CIRCULATIONAHA.118.034273 10.1007/s40119-021-00240-8 10.1185/03007995.2014.965774 10.1186/s41927-021-00231-1 10.1161/JAHA.120.016839 10.1016/S0140-6736(14)61399-4 10.1080/03007995.2018.1477747 10.1001/jamacardio.2017.0911 10.1093/ijpp/riab085 10.1016/j.atherosclerosis.2021.11.022 10.1093/eurheartj/ehx144 10.1007/s41669-021-00300-8 |
| ContentType | Journal Article |
| Copyright | Copyright: © 2023 Al Faraidy et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. COPYRIGHT 2023 Public Library of Science 2023 Al Faraidy et al. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. 2023 Al Faraidy et al 2023 Al Faraidy et al 2023 Al Faraidy et al. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| Copyright_xml | – notice: Copyright: © 2023 Al Faraidy et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. – notice: COPYRIGHT 2023 Public Library of Science – notice: 2023 Al Faraidy et al. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: 2023 Al Faraidy et al 2023 Al Faraidy et al – notice: 2023 Al Faraidy et al. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM IOV ISR 3V. 7QG 7QL 7QO 7RV 7SN 7SS 7T5 7TG 7TM 7U9 7X2 7X7 7XB 88E 8AO 8C1 8FD 8FE 8FG 8FH 8FI 8FJ 8FK ABJCF ABUWG AEUYN AFKRA ARAPS ATCPS AZQEC BBNVY BENPR BGLVJ BHPHI C1K CCPQU COVID D1I DWQXO FR3 FYUFA GHDGH GNUQQ H94 HCIFZ K9. KB. KB0 KL. L6V LK8 M0K M0S M1P M7N M7P M7S NAPCQ P5Z P62 P64 PATMY PDBOC PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQGLB PQQKQ PQUKI PRINS PTHSS PYCSY RC3 7X8 5PM DOA |
| DOI | 10.1371/journal.pone.0278821 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Gale In Context: Opposing Viewpoints Gale In Context: Science ProQuest Central (Corporate) Animal Behavior Abstracts Bacteriology Abstracts (Microbiology B) Biotechnology Research Abstracts Nursing & Allied Health Database Ecology Abstracts Entomology Abstracts (Full archive) Immunology Abstracts Meteorological & Geoastrophysical Abstracts Nucleic Acids Abstracts Virology and AIDS Abstracts Agricultural Science Collection Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) ProQuest Pharma Collection Public Health Database Technology Research Database ProQuest SciTech Collection ProQuest Technology Collection ProQuest Natural Science Collection ProQuest Hospital Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) Materials Science & Engineering Collection ProQuest Central (Alumni) ProQuest One Sustainability ProQuest Central UK/Ireland Advanced Technologies & Aerospace Collection Agricultural & Environmental Science Collection ProQuest Central Essentials Biological Science Collection ProQuest Central Technology Collection Natural Science Collection Environmental Sciences and Pollution Management ProQuest One Community College Coronavirus Research Database ProQuest Materials Science Collection ProQuest Central Engineering Research Database Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student AIDS and Cancer Research Abstracts SciTech Premium Collection ProQuest Health & Medical Complete (Alumni) Materials Science Database Nursing & Allied Health Database (Alumni Edition) Meteorological & Geoastrophysical Abstracts - Academic ProQuest Engineering Collection Biological Sciences Agricultural Science Database ProQuest Health & Medical Collection Medical Database Algology Mycology and Protozoology Abstracts (Microbiology C) Biological Science Database Engineering Database Nursing & Allied Health Premium Advanced Technologies & Aerospace Database ProQuest Advanced Technologies & Aerospace Collection Biotechnology and BioEngineering Abstracts Environmental Science Database Materials Science Collection ProQuest Central Premium ProQuest One Academic Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Applied & Life Sciences ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China Engineering Collection Environmental Science Collection Genetics Abstracts MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Agricultural Science Database Publicly Available Content Database ProQuest Central Student ProQuest Advanced Technologies & Aerospace Collection ProQuest Central Essentials Nucleic Acids Abstracts SciTech Premium Collection ProQuest Central China Environmental Sciences and Pollution Management ProQuest One Applied & Life Sciences ProQuest One Sustainability Health Research Premium Collection Meteorological & Geoastrophysical Abstracts Natural Science Collection Health & Medical Research Collection Biological Science Collection ProQuest Central (New) ProQuest Medical Library (Alumni) Engineering Collection Advanced Technologies & Aerospace Collection Engineering Database Virology and AIDS Abstracts ProQuest Biological Science Collection ProQuest One Academic Eastern Edition Agricultural Science Collection Coronavirus Research Database ProQuest Hospital Collection ProQuest Technology Collection Health Research Premium Collection (Alumni) Biological Science Database Ecology Abstracts ProQuest Hospital Collection (Alumni) Biotechnology and BioEngineering Abstracts Environmental Science Collection Entomology Abstracts Nursing & Allied Health Premium ProQuest Health & Medical Complete ProQuest One Academic UKI Edition Environmental Science Database ProQuest Nursing & Allied Health Source (Alumni) Engineering Research Database ProQuest One Academic Meteorological & Geoastrophysical Abstracts - Academic ProQuest One Academic (New) Technology Collection Technology Research Database ProQuest One Academic Middle East (New) Materials Science Collection ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Natural Science Collection ProQuest Pharma Collection ProQuest Central ProQuest Health & Medical Research Collection Genetics Abstracts ProQuest Engineering Collection Biotechnology Research Abstracts Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Bacteriology Abstracts (Microbiology B) Algology Mycology and Protozoology Abstracts (Microbiology C) Agricultural & Environmental Science Collection AIDS and Cancer Research Abstracts Materials Science Database ProQuest Materials Science Collection ProQuest Public Health ProQuest Nursing & Allied Health Source ProQuest SciTech Collection Advanced Technologies & Aerospace Database ProQuest Medical Library Animal Behavior Abstracts Materials Science & Engineering Collection Immunology Abstracts ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE Agricultural Science Database |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 4 dbid: 8FG name: ProQuest Technology Collection url: https://search.proquest.com/technologycollection1 sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Sciences (General) |
| DocumentTitleAlternate | Evolocumab Use in Hyperlipidemia in Saudi Arabia and Kuwait: Results from the observational ZERBINI Study |
| EISSN | 1932-6203 |
| ExternalDocumentID | 2767425534 oai_doaj_org_article_0349013c5eb540dfbf9b03b8f524530d PMC9858091 A733942697 36662739 10_1371_journal_pone_0278821 |
| Genre | Journal Article Observational Study |
| GeographicLocations | Saudi Arabia Kuwait Middle East |
| GeographicLocations_xml | – name: Saudi Arabia – name: Kuwait – name: Middle East |
| GrantInformation_xml | – fundername: ; |
| GroupedDBID | --- 123 29O 2WC 53G 5VS 7RV 7X2 7X7 7XC 88E 8AO 8C1 8CJ 8FE 8FG 8FH 8FI 8FJ A8Z AAFWJ AAUCC AAWOE AAYXX ABDBF ABIVO ABJCF ABUWG ACGFO ACIHN ACIWK ACPRK ACUHS ADBBV AEAQA AENEX AEUYN AFKRA AFPKN AFRAH AHMBA ALIPV ALMA_UNASSIGNED_HOLDINGS AOIJS APEBS ARAPS ATCPS BAWUL BBNVY BCNDV BENPR BGLVJ BHPHI BKEYQ BPHCQ BVXVI BWKFM CCPQU CITATION CS3 D1I D1J D1K DIK DU5 E3Z EAP EAS EBD EMOBN ESX EX3 F5P FPL FYUFA GROUPED_DOAJ GX1 HCIFZ HH5 HMCUK HYE IAO IEA IGS IHR IHW INH INR IOV IPY ISE ISR ITC K6- KB. KQ8 L6V LK5 LK8 M0K M1P M48 M7P M7R M7S M~E NAPCQ O5R O5S OK1 OVT P2P P62 PATMY PDBOC PHGZM PHGZT PIMPY PQQKQ PROAC PSQYO PTHSS PV9 PYCSY RNS RPM RZL SV3 TR2 UKHRP WOQ WOW ~02 ~KM 3V. ADRAZ BBORY CGR CUY CVF ECM EIF IPNFZ NPM RIG PMFND 7QG 7QL 7QO 7SN 7SS 7T5 7TG 7TM 7U9 7XB 8FD 8FK AZQEC C1K COVID DWQXO FR3 GNUQQ H94 K9. KL. M7N P64 PJZUB PKEHL PPXIY PQEST PQGLB PQUKI PRINS RC3 7X8 5PM PUEGO AAPBV ABPTK N95 |
| ID | FETCH-LOGICAL-c692t-88ae41fac3a1afdd5c759d68211bacb7fefbdc04f80e802cb9de9fd9cf1547443 |
| IEDL.DBID | M48 |
| ISSN | 1932-6203 |
| IngestDate | Sun Jun 04 06:37:09 EDT 2023 Wed Aug 27 01:21:40 EDT 2025 Thu Aug 21 18:38:48 EDT 2025 Fri Jul 11 05:07:56 EDT 2025 Fri Jul 25 11:31:18 EDT 2025 Tue Jun 17 20:57:38 EDT 2025 Tue Jun 10 20:22:03 EDT 2025 Fri Jun 27 05:56:58 EDT 2025 Fri Jun 27 06:12:45 EDT 2025 Thu May 22 21:07:25 EDT 2025 Wed Feb 19 02:25:20 EST 2025 Tue Jul 01 00:48:49 EDT 2025 Thu Apr 24 22:54:17 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Language | English |
| License | Copyright: © 2023 Al Faraidy et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Creative Commons Attribution License |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c692t-88ae41fac3a1afdd5c759d68211bacb7fefbdc04f80e802cb9de9fd9cf1547443 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 ObjectType-Article-2 ObjectType-Undefined-1 ObjectType-Feature-3 content type line 23 Competing Interests: The authors MS, MAJ and RD have declared that no competing interests exist KF: I have read the journal’s policy and the authors of this manuscript have the following competing interests: Consultancies from: Saudi Heart Association; Saudi Council for Health Specialties Commission; Gulf Intervention Society; Amgen; Novartis; Sanofi; Medtronic; Boehringer Ingelheim; Lectures from: Amgen; Novartis; Sanofi; Medtronic; Boehringer Ingelheim; Clinical studies from: Amgen MA: I have read the journal’s policy and the authors of this manuscript have the following competing interests: Lectures from: Amgen, Sanofi, AstraZeneca, Bayer,Boehringer Ingelheim, MSD, Novartis, Pfizer, Novonordisk, Servier, Abbott, Algorithm GAH: I have read the journal’s policy and the authors of this manuscript have the following competing interests: Lectures from Amgen; Boehringer Ingelhein; Novartis. Clinical studies from: Amgen. AAQ: I have read the journal’s policy and the authors of this manuscript have the following competing interests: Lectures from Amgen; Novartis. Clinical studies and research grants from Amgen; Other: GHA FAN: I have read the journal’s policy and the authors of this manuscript have the following competing interests: Consultancies, lectures and Clinical studies from Amgen ZA: I have read the journal’s policy and the authors of this manuscript have the following competing interests: Consultancies from: AlBorg Diagnostic; Lectures from: Amgen; Sanofi; Pfizer. Clinical studies from: Amgen. Research grants from: King Abdulaziz University A. Essam: I have read the journal’s policy and the authors of this manuscript have the following competing interests: employed by the funder of the study, Amgen. A. Emara: I have read the journal’s policy and the authors of this manuscript have the following competing interests: employed by the funder of the study, Amgen. This does not alter our adherence to PLOS ONE policies on sharing data and materials. |
| ORCID | 0000-0003-0237-9782 |
| OpenAccessLink | http://journals.scholarsportal.info/openUrl.xqy?doi=10.1371/journal.pone.0278821 |
| PMID | 36662739 |
| PQID | 2767425534 |
| PQPubID | 1436336 |
| PageCount | e0278821 |
| ParticipantIDs | plos_journals_2767425534 doaj_primary_oai_doaj_org_article_0349013c5eb540dfbf9b03b8f524530d pubmedcentral_primary_oai_pubmedcentral_nih_gov_9858091 proquest_miscellaneous_2768230321 proquest_journals_2767425534 gale_infotracmisc_A733942697 gale_infotracacademiconefile_A733942697 gale_incontextgauss_ISR_A733942697 gale_incontextgauss_IOV_A733942697 gale_healthsolutions_A733942697 pubmed_primary_36662739 crossref_primary_10_1371_journal_pone_0278821 crossref_citationtrail_10_1371_journal_pone_0278821 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2023-01-20 |
| PublicationDateYYYYMMDD | 2023-01-20 |
| PublicationDate_xml | – month: 01 year: 2023 text: 2023-01-20 day: 20 |
| PublicationDecade | 2020 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States – name: San Francisco – name: San Francisco, CA USA |
| PublicationTitle | PloS one |
| PublicationTitleAlternate | PLoS One |
| PublicationYear | 2023 |
| Publisher | Public Library of Science Public Library of Science (PLoS) |
| Publisher_xml | – name: Public Library of Science – name: Public Library of Science (PLoS) |
| References | V Guglielmi (pone.0278821.ref036) 2017; 263 BA Ference (pone.0278821.ref014) 2017; 38 K. Ray (pone.0278821.ref024) 2020; 41 JM Lucca (pone.0278821.ref037) 2022; 30 GA Roth (pone.0278821.ref002) 2020; 76 K Turk-Adawi (pone.0278821.ref004) 2017; 15 MB Mortensen (pone.0278821.ref011) 2020; 396 CA Forbes (pone.0278821.ref019) 2018; 34 AF Schmidt (pone.0278821.ref016) 2020; 10 M Gupta (pone.0278821.ref020) 2022 MS Sabatine (pone.0278821.ref022) 2017; 376 B Sarak (pone.0278821.ref043) 2021; 14 LD Colantonio (pone.0278821.ref035) 2017; 2 A Alghamdi (pone.0278821.ref030) 2022; 6 M Wake (pone.0278821.ref033) 2019; 282 PE Penson (pone.0278821.ref015) 2020; 18 WHO (pone.0278821.ref001) 2021 N Aljefree (pone.0278821.ref005) 2015; 2015 MJ Koren (pone.0278821.ref025) 2019; 74 L Racette (pone.0278821.ref041) 2022; 129 SM Grundy (pone.0278821.ref027) 2019; 139 ML Daviglus (pone.0278821.ref034) 2021; 10 E Caton (pone.0278821.ref040) 2021; 5 TM Ramahi (pone.0278821.ref003) 2010; 22 F Mach (pone.0278821.ref026) 2020; 41 X Ge (pone.0278821.ref021) 2021; 2021 K Tsioufis (pone.0278821.ref032) 2021; 10 Z Zhao (pone.0278821.ref017) 2019; 98 N Ziadé (pone.0278821.ref039) 2020; 23 FJ Raal (pone.0278821.ref023) 2015; 385 M Athamneh (pone.0278821.ref038) 2021; 57 K Al-Rasadi (pone.0278821.ref029) 2014; 30 KF Alhabib (pone.0278821.ref008) 2021; 16 N Alsayed (pone.0278821.ref007) 2022; 343 CE Chiang (pone.0278821.ref010) 2016; 23 A Karatasakis (pone.0278821.ref018) SH Naderi (pone.0278821.ref031) 2012; 125 pone.0278821.ref006 OL Ramey (pone.0278821.ref042) 2022 G Mu (pone.0278821.ref028) 2020; 37 SM Abdullah (pone.0278821.ref012) 2018; 138 SN Al Sifri (pone.0278821.ref009) 2014; 9 JG Robinson (pone.0278821.ref013) 2018; 7 |
| References_xml | – volume: 76 start-page: 2982 issue: 25 year: 2020 ident: pone.0278821.ref002 article-title: Global Burden of Cardiovascular Diseases and Risk Factors, 1990–2019: Update From the GBD 2019 Study. publication-title: J Am Coll Cardiol doi: 10.1016/j.jacc.2020.11.010 – volume: 98 issue: 6 year: 2019 ident: pone.0278821.ref017 article-title: Comparative efficacy and safety of lipid-lowering agents in patients with hypercholesterolemia: A frequentist network meta-analysis. publication-title: Medicine (Baltimore). doi: 10.1097/MD.0000000000014400 – volume: 41 start-page: 111 issue: 1 year: 2020 ident: pone.0278821.ref026 article-title: 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular riskThe Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). publication-title: Eur Heart J doi: 10.1093/eurheartj/ehz455 – volume: 129 start-page: 258 issue: 3 year: 2022 ident: pone.0278821.ref041 article-title: The Impact of the Coronavirus Disease 2019 Pandemic on Adherence to Ocular Hypotensive Medication in Patients with Primary Open-Angle Glaucoma. publication-title: Ophthalmology doi: 10.1016/j.ophtha.2021.10.009 – volume: 9 issue: 1 year: 2014 ident: pone.0278821.ref009 article-title: Results of the Dyslipidemia International Study (DYSIS)-Middle East: clinical perspective on the prevalence and characteristics of lipid abnormalities in the setting of chronic statin treatment. publication-title: PLoS One. doi: 10.1371/journal.pone.0084350 – volume: 37 start-page: 1496 issue: 4 year: 2020 ident: pone.0278821.ref028 article-title: Efficacy and Safety of PCSK9 Monoclonal Antibodies in Patients at High Cardiovascular Risk: An Updated Systematic Review and Meta-Analysis of 32 Randomized Controlled Trials. publication-title: Adv Ther. doi: 10.1007/s12325-020-01259-4 – ident: pone.0278821.ref006 – volume: 10 issue: 10 year: 2020 ident: pone.0278821.ref016 article-title: PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease. publication-title: Cochrane database Syst Rev. – volume: 41 issue: Supplement_2 year: 2020 ident: pone.0278821.ref024 article-title: Does Evolocumab use in Europe match 2019 ESC/EAS lipid guidelines? Results from the HEYMANS study. publication-title: Eur Heart J – volume: 2015 start-page: 1 year: 2015 ident: pone.0278821.ref005 article-title: Prevalence of Cardiovascular Disease and Associated Risk Factors among Adult Population in the Gulf Region: A Systematic Review. publication-title: Adv Public Heal. doi: 10.1155/2015/235101 – year: 2022 ident: pone.0278821.ref042 article-title: Medication adherence in Medicare-enrolled older adults with asthma before and during the coronavirus disease 2019 pandemic. publication-title: Ann Allergy Asthma Immunol – volume: 282 start-page: 19 year: 2019 ident: pone.0278821.ref033 article-title: Adherence and persistence to hyperlipidemia medications in patients with atherosclerotic cardiovascular disease and those with diabetes mellitus based on administrative claims data in Japan publication-title: Atherosclerosis doi: 10.1016/j.atherosclerosis.2018.12.026 – volume: 57 start-page: 1 issue: 1 year: 2021 ident: pone.0278821.ref038 article-title: Knowledge, attitudes, and impact of COVID-19 pandemic among neurology patients in Jordan: a cross-sectional study. publication-title: Egypt J Neurol Psychiatry Neurosurg doi: 10.1186/s41983-021-00354-9 – volume: 7 issue: 20 year: 2018 ident: pone.0278821.ref013 article-title: Eradicating the Burden of Atherosclerotic Cardiovascular Disease by Lowering Apolipoprotein B Lipoproteins Earlier in Life. publication-title: J Am Heart Assoc doi: 10.1161/JAHA.118.009778 – volume: 14 start-page: 445 issue: 4 year: 2021 ident: pone.0278821.ref043 article-title: Lipid Testing, Lipid-Modifying Therapy, and PCSK9 (Proprotein Convertase Subtilisin-Kexin Type 9) Inhibitor Eligibility in 27 979 Patients With Incident Acute Coronary Syndrome. publication-title: Circ Cardiovasc Qual Outcomes. doi: 10.1161/CIRCOUTCOMES.120.006646 – volume: 396 start-page: 1644 issue: 10263 year: 2020 ident: pone.0278821.ref011 article-title: Elevated LDL cholesterol and increased risk of myocardial infarction and atherosclerotic cardiovascular disease in individuals aged 70–100 years: a contemporary primary prevention cohort publication-title: Lancet (London, England). doi: 10.1016/S0140-6736(20)32233-9 – volume: 2021 year: 2021 ident: pone.0278821.ref021 article-title: A Systematic Review and Meta-Analysis of Therapeutic Efficacy and Safety of Alirocumab and Evolocumab on Familial Hypercholesterolemia publication-title: Biomed Res Int – volume: 23 start-page: 1550 issue: 11 year: 2020 ident: pone.0278821.ref039 article-title: Impact of the COVID-19 pandemic on patients with chronic rheumatic diseases: A study in 15 Arab countries. publication-title: Int J Rheum Dis. doi: 10.1111/1756-185X.13960 – volume: 16 issue: 6 year: 2021 ident: pone.0278821.ref008 article-title: Familial Hypercholesterolemia in the Arabian Gulf Region: Clinical results of the Gulf FH Registry. publication-title: PLoS One. doi: 10.1371/journal.pone.0251560 – volume: 376 start-page: 1713 issue: 18 year: 2017 ident: pone.0278821.ref022 article-title: Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease publication-title: N Engl J Med doi: 10.1056/NEJMoa1615664 – volume: 125 start-page: 882 issue: 9 year: 2012 ident: pone.0278821.ref031 article-title: Adherence to drugs that prevent cardiovascular disease: meta-analysis on 376,162 patients publication-title: Am J Med doi: 10.1016/j.amjmed.2011.12.013 – ident: pone.0278821.ref018 article-title: Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta-Analysis of 35 Randomized Controlled Trials. doi: 10.1161/JAHA.117.006910 – volume: 74 start-page: 2132 issue: 17 year: 2019 ident: pone.0278821.ref025 article-title: Long-Term Efficacy and Safety of Evolocumab in Patients With Hypercholesterolemia publication-title: J Am Coll Cardiol doi: 10.1016/j.jacc.2019.08.1024 – volume: 263 start-page: 36 year: 2017 ident: pone.0278821.ref036 article-title: Effectiveness of adherence to lipid lowering therapy on LDL-cholesterol in patients with very high cardiovascular risk: A real-world evidence study in primary care publication-title: Atherosclerosis doi: 10.1016/j.atherosclerosis.2017.05.018 – volume: 15 start-page: 106 issue: 2 year: 2017 ident: pone.0278821.ref004 article-title: Cardiovascular disease in the Eastern Mediterranean region: epidemiology and risk factor burden. publication-title: Nat Rev Cardiol doi: 10.1038/nrcardio.2017.138 – volume: 23 start-page: 552 issue: 5 year: 2016 ident: pone.0278821.ref010 article-title: Suboptimal Control of Lipid Levels: Results from 29 Countries Participating in the Centralized Pan-Regional Surveys on the Undertreatment of Hypercholesterolaemia (CEPHEUS). publication-title: J Atheroscler Thromb doi: 10.5551/jat.31179 – volume: 18 start-page: 1 issue: 1 year: 2020 ident: pone.0278821.ref015 article-title: LDL-C: Lower is better for longer—Even at low risk. publication-title: BMC Med. doi: 10.1186/s12916-020-01792-7 – volume: 138 start-page: 2315 issue: 21 year: 2018 ident: pone.0278821.ref012 article-title: Long-Term Association of Low-Density Lipoprotein Cholesterol with Cardiovascular Mortality in Individuals at Low 10-Year Risk of Atherosclerotic Cardiovascular Disease: Results from the Cooper Center Longitudinal Study publication-title: Circulation doi: 10.1161/CIRCULATIONAHA.118.034273 – volume: 10 start-page: 445 issue: 2 year: 2021 ident: pone.0278821.ref032 article-title: Real-world Evidence for Adherence and Persistence with Atorvastatin Therapy. publication-title: Cardiol Ther doi: 10.1007/s40119-021-00240-8 – volume: 30 start-page: 2429 issue: 12 year: 2014 ident: pone.0278821.ref029 article-title: Therapeutic lipid target achievements among high and highest risk patients: results from the CEPHEUS study in the Arabian Gulf. publication-title: Curr Med Res Opin. doi: 10.1185/03007995.2014.965774 – volume: 5 issue: 1 year: 2021 ident: pone.0278821.ref040 article-title: The impact of COVID-19 on self-management behaviours and healthcare access for people with inflammatory arthritis. publication-title: BMC Rheumatol. doi: 10.1186/s41927-021-00231-1 – volume: 10 start-page: 1 issue: 1 year: 2021 ident: pone.0278821.ref034 article-title: Effects of Evolocumab on Low-Density Lipoprotein Cholesterol, Non-High Density Lipoprotein Cholesterol, Apolipoprotein B, and Lipoprotein(a) by Race and Ethnicity: A Meta-Analysis of Individual Participant Data From Double-Blind and Open-Label Extension Studies. publication-title: J Am Heart Assoc doi: 10.1161/JAHA.120.016839 – volume: 385 start-page: 331 issue: 9965 year: 2015 ident: pone.0278821.ref023 article-title: PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial. publication-title: Lancet doi: 10.1016/S0140-6736(14)61399-4 – volume: 22 issue: SUPPL. 3 year: 2010 ident: pone.0278821.ref003 article-title: Cardiovascular disease in the asia middle east region: Global trends and local implications. publication-title: Asia-Pacific J Public Heal. – volume: 34 start-page: 1613 issue: 9 year: 2018 ident: pone.0278821.ref019 article-title: A systematic literature review comparing methods for the measurement of patient persistence and adherence. publication-title: Curr Med Res Opin. doi: 10.1080/03007995.2018.1477747 – volume: 2 start-page: 890 issue: 8 year: 2017 ident: pone.0278821.ref035 article-title: Adherence to High-Intensity Statins Following a Myocardial Infarction Hospitalization Among Medicare Beneficiaries publication-title: JAMA Cardiol doi: 10.1001/jamacardio.2017.0911 – volume: 30 start-page: 136 issue: 2 year: 2022 ident: pone.0278821.ref037 article-title: Patient satisfaction with pharmaceutical care services for chronic diseases and their medication adherence during COVID-19 in Saudi Arabia publication-title: Int J Pharm Pract doi: 10.1093/ijpp/riab085 – volume: 343 start-page: 28 year: 2022 ident: pone.0278821.ref007 article-title: Consensus clinical recommendations for the management of plasma lipid disorders in the Middle East: 2021 update publication-title: Atherosclerosis doi: 10.1016/j.atherosclerosis.2021.11.022 – volume: 139 start-page: E1082 issue: 25 year: 2019 ident: pone.0278821.ref027 article-title: AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines publication-title: Circulation – year: 2021 ident: pone.0278821.ref001 publication-title: Cardiovascular diseases (CVDs) [Internet]. – volume: 38 start-page: 2459 issue: 32 year: 2017 ident: pone.0278821.ref014 article-title: Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel publication-title: Eur Heart J doi: 10.1093/eurheartj/ehx144 – year: 2022 ident: pone.0278821.ref020 article-title: Real-world Insights into Evolocumab Use in Patients with Hyperlipidemia: Canadian Analysis from the ZERBINI Study. publication-title: CJC Open. – volume: 6 start-page: 277 issue: 2 year: 2022 ident: pone.0278821.ref030 article-title: Cost-Effectiveness Analysis of Evolocumab for the Treatment of Dyslipidemia in the Kingdom of Saudi Arabia. publication-title: PharmacoEconomics—open. doi: 10.1007/s41669-021-00300-8 |
| SSID | ssj0053866 |
| Score | 2.4368079 |
| Snippet | Dyslipidemia is a prevalent condition with significant morbidity and mortality across the world, including in the Arabian Gulf. The present study aimed to... Objectives Dyslipidemia is a prevalent condition with significant morbidity and mortality across the world, including in the Arabian Gulf. The present study... ObjectivesDyslipidemia is a prevalent condition with significant morbidity and mortality across the world, including in the Arabian Gulf. The present study... Objectives Dyslipidemia is a prevalent condition with significant morbidity and mortality across the world, including in the Arabian Gulf. The present study... |
| SourceID | plos doaj pubmedcentral proquest gale pubmed crossref |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source |
| StartPage | e0278821 |
| SubjectTerms | Adult Anticholesteremic Agents - adverse effects Biology and Life Sciences Cardiovascular disease Cholesterol Cholesterol, LDL Coronary artery disease Diabetes Drug dosages Drug therapy Dyslipidemia Health services Heart attacks Heart diseases Humans Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use Hyperlipidemia Hyperlipidemias - drug therapy Hypertension Kuwait - epidemiology Lipids Local population Low density lipoprotein Medicine and Health Sciences Metabolic disorders Monoclonal antibodies Morbidity Observational studies Patients People and places Prospective Studies Retrospective Studies Saudi Arabia Statins Statistical analysis |
| SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELbQnrggyqsLbTEICTikzcZOnHBrUasuiCJtKaq4RH7SlZZkVW-ExJ_iLzKTeKMNqlQOHB1PLHs8M56xPZ8JeQVmESyv0FFqrY240EkknUqjODeMx4oz1sIufjrLTi_4h8v0cuOpL7wT1sEDd4w7QPwUcFN0ahU4F8YpV6iYqdylCU9ZbND6wpq3DqY6GwxanGUhUY6JyUGYl_1lXdl9PGvLk8lgIWrx-nurPFouan-Ty_n3zcmNpejkPrkXfEh62PV9i9yx1QOyFbTU0zcBSvrtQ_K7za_9hd42rVW_AQulFlaWQjCMeK_WUAWFkCRJlxsYRp7WFbVgw2rd_JCKNt7SeUV9o3ADx1Pcx6VXEMxeL-bdY7MS689lY-bQQ6mgLCtDPzY_5Xz1js6shy55imktFJxP-u14djQ9m3YdekQuTo6_vD-NwhMNkc6KZBXlubR84qRmciKdMakWaWEyYO9ESa2Es04ZHXOXxzaPE60KYwtnCu3AdROcs8dkVMFotglV0ACeCSpnci4zJ6VKBTRpJESsudBjwtbzVeqAX47PaCzK9lBOQBzTsb_EWS7DLI9J1P-17PA7bqE_QlHoaRF9u_0AMlkGmSxvk8kxeY6CVHaprL0NKQ8FYwXmDosxedlSIAJHhVd8vsvG-3L6-es_EJ3PBkSvA5GrgR1ahrQKGBMiew0odwaUYEf0oHobxX7NFV8miPMEESfj8OdaFW6uftFXY6N4ba-yddPS4EEuQ74-6TSn5yzL8O0BVoyJGOjUgPXDmmp-1QKgF3mag84__R9z9YzcTcBvxV21JN4ho9V1Y3fBz1ypvdak_AHhe4Gg priority: 102 providerName: Directory of Open Access Journals – databaseName: Public Health Database dbid: 8C1 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1Lb9QwELZguXBBlFcXChiEBBzSJnEeDhfUVq26IIq0pajiEvnZrrQky3ojJP4Uf5GZxBsaVAFHxxPLGXsm4xnPN4S8ALUImjdXQWqMCZJcxYGwMg1CrlkSyoSxFnbxw3F2dJq8O0vPvMPN-WuVa53YKmpdK_SR78SIOgP2L0veLr4FWDUKo6u-hMZ1ciMCHYzY-Xy_v-IBspxlPl2O5dGOX53tRV2ZbYy48Tga_I5a1P5eN48W89pdZXj-eX_y0g_p8Da55S1Jutst_Qa5Zqo7ZMPLqqOvPKD067vkZ5tl-wNtblrL3g0LrRZclsKRGFFfjaYSGj5Vki4uIRk5WlfUgCarVfNVSNo4Q2cVdY1EN46j6M2lF3CkXc5nXclZgf0notEzmKGQ0BaVpu-b72K2ekOnxsGUHMXkFgomKP1yMN2bHE-6Cd0jp4cHn_aPAl-oIVBZEa8CzoVJIisUE5GwWqcqTwudAXsjKZTMrbFSqzCxPDQ8jJUstCmsLpQFAy5PEnafjCr4mk1CJQyAkUFpNU9EZoWQaQ5DagHnVp6rMWHr9SqVRzHHYhrzsg3N5XCa6dhf4iqXfpXHJOjfWnQoHv-g38Ot0NMiBnf7oF6el16kS0T2AQNapUaC2auttIUMmeQ2jZOUhXpMnuJGKruE1l6TlLs5YwVmEOdj8rylQByOCi_6nIvGuXLy8fN_EJ1MB0QvPZGtgR1K-OQK-CbE9xpQbg0oQZuoQfcmbvs1V1z5W-7gzbUoXN39rO_GQfHyXmXqpqXBcC5Dvj7oJKfnLMuwAgErxiQfyNSA9cOeanbRwqAXPOVg7T78-7QekZsx2KXoNYvDLTJaLRvzGOzIlXzSKotfQWZ5TQ priority: 102 providerName: ProQuest |
| Title | Multizonal observational study conducted by clinical practitioners on evolocumab use in subjects with hyperlipidemia in Saudi Arabia and Kuwait: Results from the ZERBINI study |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/36662739 https://www.proquest.com/docview/2767425534 https://www.proquest.com/docview/2768230321 https://pubmed.ncbi.nlm.nih.gov/PMC9858091 https://doaj.org/article/0349013c5eb540dfbf9b03b8f524530d http://dx.doi.org/10.1371/journal.pone.0278821 |
| Volume | 18 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3db9MwELfG9sILYnytMIpBSMBDpjRO6gQJoW3aWEErqKOo2kvkz61SSUrTiI9_in-ROyeNFlQEvERyfLacs-9yZ_t-R8hTUIugebnyImOMF3IVeMLKyPNjzUJfhow52MXTYf9kHL6dRJMNssrZWjOwWOvaYT6p8WK29-3L99cg8K9c1gbeWzXam-eZ2cOTtBgjy7fg38QxmcNp2JwrgHS700u0Wrx-4LM6mO5PvbR-Vg7Tv9Hcm_NZXqwzS3-_XXnld3V8k9yo7Uy6Xy2MbbJhsltku5bkgj6v4aZf3CY_XQzuD7TIaS6bTVooOehZCg4zYsIaTSUU6kBKOr-Cc1TQPKMG9Fyuys9C0rIwdJrRopS4yVNQ3Oull-DwLmbTKiGtwPozUeopjFBIKItM03flVzFdvqQjU8CQCoqhLxQMVHp-NDoYDAfVgO6Q8fHRx8MTr07j4Kl-Eiy9OBYm7FmhmOgJq3WkeJToPrC3J4WS3BortfJDG_sm9gMlE20SqxNlwbzjYcjuks0MvmaHUAkd4LmhtDoORd8KISMOXWoBXm3MVYew1XylqsY4x1Qbs9Qd3HHwdSr2pzjLaT3LHeI1reYVxsdf6A9wKTS0iNDtXuSLi7QW-BRxf8C8VpGRYBRrK20ifSZjGwVhxHzdIY9wIaVVuGujZ9J9zliC8cW8Q544CkTpyPAa0IUoiyIdvP_0D0RnoxbRs5rI5sAOJerQC_gmRP9qUe62KEHXqFb1Di77FVeKNEAsKPBKWQgtV6KwvvpxU42d4tW-zOSlo8HDXoZ8vVdJTsNZ1sf8BCzpEN6SqRbr2zXZ9NKBpCdxFIMtfP8_5_YBuR6AGYubbIG_SzaXi9I8BLNzKbvkGp9weMaHPXwev-mSrYOj4YdR123kdJ2m-QXXz4yd |
| linkProvider | Scholars Portal |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwELbKcoALory6UKhBIOCQNhsnsYOEUFtadekDqS9VXIKf7UolWZqNKvhR8BeZSbKhQRVw6dHxxLLH4_GM7fmGkOegFkHzcu1F1lov5DrwpFOR5wvDQl-FjFWwi9s78cZB-OEoOpohP6axMPiscqoTK0Vtco1n5EsBos6A_cvCd-OvHmaNwtvVaQqNWiw27bdzcNmKt8P3ML8vgmB9bX91w2uyCng6ToKJJ4S04cBJzeRAOmMizaPExAI8ISW14s46ZbQfOuFb4QdaJcYmziTagbXBw5BBu9fIdRgFR6x-sdo-KQHdEcdNeB7jg6VGGhbHeWYX8YZPBIPO9ldlCWj3gt74NC8uM3T_fK95YQNcv01uNZYrXa5FbZbM2OwOmW10Q0FfNQDWr--Sn1VU73e08Wmu2mNfKFVgthRccESZtYYqKDShmXR8ATmpoHlGLWjOXJdfpKJlYekoo0Wp8NiooHh6TE_AhT47HdUpbiXW78nSjKCHUkFZZoZuludyNHlDd20BXSooBtNQMHnpp7XdleHOsO7QPXJwJVN4n_QyGM0coQoawJtI5YwIZeykVBGHJo0EP1lw3SdsOl-pblDTMXnHaVpdBXLwnmr2pzjLaTPLfeK1f41r1JB_0K-gKLS0iPldfcjPjtNGhaSIJAQGu46sAjPbOOUS5TMlXBSEEfNNnyygIKV1AG2rudJlzliCEcu8T55VFIj7keHDomNZFkU6_Hj4H0R7ux2ilw2Ry4EdWjbBHDAmxBPrUM53KEF76U71HIr9lCtF-nudw5_TpXB59dO2GhvFx4KZzcuKBq-PGfL1Qb1yWs6yGDMesKRPeGdNdVjfrclGJxXseiIiAdb1w793a4Hc2Njf3kq3hjubj8jNAGxiPLEL_HnSm5yV9jHYsBP1pFIclHy-ak31C-_duRc |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwELZKkRAXRHl1oVCDQMAhbTZO4gQJoZa26rJQUB-o4hL8bFcqybLZqII_xZ1fx0ziDQ2qgEuPiSeWY48_z9iebwh5DLAIyMuVFxljvJCrwBNWRp6faBb6MmSspl18txNvH4RvDqPDOfJzFguD1ypnmFgDtS4U7pGvBsg6A_YvC1etuxbxYWPr1firhxmk8KR1lk6jUZGh-XYK7lv5crABY_0kCLY2919vey7DgKfiNJh6SSJM2LdCMdEXVutI8SjVcQJekRRKcmus1MoPbeKbxA-UTLVJrU6VBcuDhyGDei-Ry5zBsglziR-2zh7gSBy7UD3G-6tOM1bGRW5W8LQvCfqdpbDOGNCuC_Pjk6I8z-j98-7mmcVw6zq55qxYutao3QKZM_kNsuBwoqTPHJn185vkRx3h-x3tfVrIdgsYnmpiWwruODLOGk0lPLgwTTo-w6JU0iKnBlC0UNUXIWlVGjrKaVlJ3EIqKe4k02NwpycnoybdrcDyPVHpEbRQSHgWuabD6lSMpi_orimhSSXFwBoK5i_9tLm7PtgZNA26RQ4uZAhvk_kc_maRUAkV4KmktDoJRWyFkBGHKrUAnznhqkfYbLwy5RjUMZHHSVYfC3LwpJruz3CUMzfKPeK1X40bBpF_yK-jKrSyyP9dvygmR5mDkwxZhcB4V5GRYHJrK20qfSYTGwVhxHzdI8uoSFkTTNuiWLbGGUsxepn3yKNaAjlAcpxNR6Iqy2zw_uN_CO3tdoSeOiFbQHco4QI74J-QW6wjudSRBCRTneJFVPtZr5TZ7zkPX86mwvnFD9tirBQvDuamqGoZPEpm2K93mpnT9iyLMfsBS3uEd-ZUp-u7JfnouKZgT5MoAUv77t-btUyuAEZlbwc7w3vkagDmMW7eBf4SmZ9OKnMfzNmpfFDjBiWfLxqofgGXxL15 |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Multizonal+observational+study+conducted+by+clinical+practitioners+on+evolocumab+use+in+subjects+with+hyperlipidemia+in+Saudi+Arabia+and+Kuwait%3A+Results+from+the+ZERBINI+study&rft.jtitle=PloS+one&rft.au=Al+Faraidy%2C+Khalid&rft.au=Akbar%2C+Mousa&rft.au=Shehri%2C+Mohamed&rft.au=Aljarallah%2C+Mohammad&rft.date=2023-01-20&rft.issn=1932-6203&rft.eissn=1932-6203&rft.volume=18&rft.issue=1&rft.spage=e0278821&rft_id=info:doi/10.1371%2Fjournal.pone.0278821&rft.externalDBID=n%2Fa&rft.externalDocID=10_1371_journal_pone_0278821 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1932-6203&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1932-6203&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1932-6203&client=summon |